![](http://core.secure.ehc.com/src/apps/news/images/news-default-image.jpg)
More than 135 abstracts accepted for presentation across all phases of drug development
Nashville, Tenn – Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023. More than 80 experts from SCRI’s research network participated in key research that will be presented at the Annual Meeting, including important updates for 64 early-phase studies as well as a number of late-phase trials for multiple types of cancer, including breast, lung, hematologic malignancies, and more.
In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
“The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A. “Skip” Burris III, MD, President, SCRI. “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
View a comprehensive list of abstracts and presentations
Noteworthy presentations
Breast Cancer
- Erika Hamilton, MD, SCRI at Tennessee Oncology, will give two oral presentations – “Efficacy and Safety Results by Age in monarchE: Adjuvant Abemaciclib Combined with Endocrine Therapy in Patients with HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer” on June 2 at 2:45pm CDT in Hall D1 and “A Phase 2 Study of HER3-DXd in Patients with Metastatic Breast Cancer” on June 5 at 11:30am CDT in Hall B1.
- Denise Yardley, MD, SCRI at Tennessee Oncology, contributed to research featured in the oral presentation, “Ribociclib and Endocrine Therapy as Adjuvant Treatment in Patients with HR+/HER2− Early Breast Cancer: Primary Results from the Phase III NATALEE Trial,” which will take place on June 2 at 2:45pm CDT in Hall D1.
Genitourinary Cancer
- Thomas Hutson, DO, PharmD, SCRI at Texas Oncology I The US Oncology Network, will deliver “Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-Up of Lenvatinib Plus Pembrolizumab vs Sunitinib in Patients with Advanced Renal Cell Carcinoma” in an oral presentation on June 5 at 11:30am CDT in Hall D1.
Lung Cancer
- Melissa Johnson, MD, SCRI at Tennessee Oncology, will present “ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer” in the ASCO Plenary Series: Rapid Abstract Updates on June 3 at 12:30pm CDT in the Arie Crown Theater. Dr. Johnson also co-authored research that will be featured in the oral presentation, “First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6 –Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer,” on June 5 at 8am CDT in Hall D2.
Melanoma/Skin Cancer
- Meredith McKean, MD, MPH, SCRI at Tennessee Oncology, participated in research that will be featured in the oral presentation, “Distant Metastasis-Free Survival Results from the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial,” on June 5 at 3pm CDT in Hall D1.
In addition to the scientific presentations, SCRI leadership will participate in and lead ASCO sessions, including:
- McKean will chair the education session, New Drugs in Oncology: Incorporation into Practice, on June 2 at 2:45pm CDT in E450.
- Benjamin Garmezy, MD, SCRI at Tennessee Oncology, will discuss “The Power of Patients' Experiences to Inform Therapeutic Decisions” in the poster discussion session, Genitourinary Cancer—Kidney and Bladder, on June 3 at 3pm CDT in E450.
- Hamilton will chair the Highlights of the Day session on June 4 at 8:15am CDT in Hall D1 and present “The Next Frontier: Resistance to ADCs and Combination Strategies” in the education session, Next-Generation Antibody-Drug Conjugates: Past, Present, and Future, on June 4 at 4:30pm CDT in Hall D2.
- Cesar Perez, MD, SCRI at Florida Cancer Specialists, will chair the Head and Neck Cancer oral abstract session on June 5 at 8am CDT in Hall B1.
- Manojkumar Bupathi, MD, MS, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, will chair the oral abstract session, Genitourinary Cancer – Kidney and Bladder, on June 5 at 11:30am CDT in E450.
Additional poster presentations with SCRI first authors
Saturday, June 3, 2023
- “Phase 1/1b Study of SY-5609, a Selective and Potent CDK7 Inhibitor, in Advanced Solid Tumors and in 2L/3L Pancreatic Ductal Adenocarcinoma in Combination with Gemcitabine +/- Nab-Paclitaxel,” Babar Bashir, MD, SCRI at Sidney Kimmel Cancer Center, 8am CDT, Hall A
- “First-in-Human Phase 1 Study of Pimicotinib, a CSF-1R Inhibitor, in Patients with Advanced Solid Tumors,” Gerald Falchook, MD, SCRI at HealthONE, 8am CDT, Hall A
- “Safety and Efficacy of DB-1303 in Patients with Advanced/Metastatic Solid Tumors: A Multicenter, Open-Label, First-in-Human, Phase 1/2a Study,” Kathleen Moore, MD, SCRI at Stephenson Cancer Center, 8am CDT, Hall A
- “BLU-222, an Oral, Potent and Selective CDK2 Inhibitor, in Patients with Advanced Solid Tumors: Phase 1 Monotherapy Dose Escalation,” Manish Patel, MD, SCRI at Florida Cancer Specialists, 8am CDT, Hall A
- “MyTACTIC: Efficacy and Safety of Atezolizumab + Chemotherapy in Patients with Advanced Unresectable/Metastatic Solid Tumors with High Tumor Mutational Burden or High Microsatellite Instability/Deficient Mismatch Repair,” David Spigel, MD, SCRI at Tennessee Oncology, 8am CDT, Hall A
- “A Phase 1 Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors,” Susanna Ulahannan, MD, MMed, SCRI at Stephenson Cancer Center, 8am CDT, Hall A
- “A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of cln-619 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors,” Judy Wang, MD, SCRI at Florida Cancer Specialists, 8am CDT, Hall A
Sunday, June 4, 2023
- “Management of Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer Who Received Brain Radiotherapy on Study in the Phase 3 CROWN Trial,” Todd Bauer, MD, SCRI at Tennessee Oncology, 8am CDT, Hall A
Monday, June 5, 2023
- “Correlating Expression of NaPi2b and FRa in High Grade Serous Ovarian Cancer,” Debra Richardson, MD, FACS, FACOG, SCRI at Stephenson Cancer Center, 1:15pm CDT, Hall A
- “Preliminary Results from ERAS-007 Plus Palbociclib in Patients with KRAS/NRAS Mutant Colorectal Cancer or KRASm Pancreatic Ductal Adenocarcinoma in HERKULES-3 Study: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Pts with Advanced Gastrointestinal Malignancies,” Susanna Ulahannan, MD, MMed, SCRI at Stephenson Cancer Center, 8am CDT, Hall A